Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK.sub.1), neurokinin-2 (NK.sub.2) and neurokinin-3 (NK.sub.3) receptors, (b) antagonists of NK.sub.1 and NK.sub.2 receptors, (c) antagonists of NK.sub.2 and NK.sub.3 receptors, (d) antagonists of NK.sub.1 and NK.sub.3 receptors, (e) antagonists of NK.sub.1 receptors, and (f) antagonists of NK.sub.2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.

Uso de um antagonista selecionado de consistir do grupo: (a) os antagonistas (NK.sub.3) dos receptors neurokinin-1 (NK.sub.1), neurokinin-2 (NK.sub.2) e neurokinin-3, (b) os antagonistas de NK.sub.1 e os receptors NK.sub.2, (c) antagonistas de NK.sub.2 e receptors NK.sub.3, (d) antagonistas de NK.sub.1 e receptors NK.sub.3, (e) antagonistas dos receptors NK.sub.1, e (f) antagonistas de NK.sub.2 para tratar sintomas e disorders associaram com uma produção e/ou um secretion do androgen. Um aspecto da invenção relaciona-se ao uso dos antagonistas suprimir production/secretion dos androgens nos mamíferos que sofrem de uma doença androgen-dependente, tal como a hiperplasia prostatic benigna e o carcinoma prostatic.